JP2020526202A5 - - Google Patents

Download PDF

Info

Publication number
JP2020526202A5
JP2020526202A5 JP2020500687A JP2020500687A JP2020526202A5 JP 2020526202 A5 JP2020526202 A5 JP 2020526202A5 JP 2020500687 A JP2020500687 A JP 2020500687A JP 2020500687 A JP2020500687 A JP 2020500687A JP 2020526202 A5 JP2020526202 A5 JP 2020526202A5
Authority
JP
Japan
Prior art keywords
seq
nucleotide sequence
amino acid
acid sequence
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020500687A
Other languages
English (en)
Japanese (ja)
Other versions
JP7028953B2 (ja
JP2020526202A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/054926 external-priority patent/WO2019012371A1/en
Publication of JP2020526202A publication Critical patent/JP2020526202A/ja
Publication of JP2020526202A5 publication Critical patent/JP2020526202A5/ja
Priority to JP2021175480A priority Critical patent/JP2022031653A/ja
Application granted granted Critical
Publication of JP7028953B2 publication Critical patent/JP7028953B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020500687A 2017-07-11 2018-07-03 Cea、muc1およびtertを含む免疫原性組成物 Expired - Fee Related JP7028953B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021175480A JP2022031653A (ja) 2017-07-11 2021-10-27 Cea、muc1およびtertを含む免疫原性組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762531227P 2017-07-11 2017-07-11
US62/531,227 2017-07-11
US201862682044P 2018-06-07 2018-06-07
US62/682,044 2018-06-07
PCT/IB2018/054926 WO2019012371A1 (en) 2017-07-11 2018-07-03 IMMUNOGENIC COMPOSITIONS COMPRISING CEA MUC1 AND TERT

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021175480A Division JP2022031653A (ja) 2017-07-11 2021-10-27 Cea、muc1およびtertを含む免疫原性組成物

Publications (3)

Publication Number Publication Date
JP2020526202A JP2020526202A (ja) 2020-08-31
JP2020526202A5 true JP2020526202A5 (enExample) 2021-03-25
JP7028953B2 JP7028953B2 (ja) 2022-03-02

Family

ID=63720720

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020500687A Expired - Fee Related JP7028953B2 (ja) 2017-07-11 2018-07-03 Cea、muc1およびtertを含む免疫原性組成物
JP2021175480A Pending JP2022031653A (ja) 2017-07-11 2021-10-27 Cea、muc1およびtertを含む免疫原性組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021175480A Pending JP2022031653A (ja) 2017-07-11 2021-10-27 Cea、muc1およびtertを含む免疫原性組成物

Country Status (16)

Country Link
US (1) US20190016775A1 (enExample)
EP (1) EP3651792A1 (enExample)
JP (2) JP7028953B2 (enExample)
KR (1) KR20200027551A (enExample)
CN (1) CN111065408A (enExample)
AU (1) AU2018300295A1 (enExample)
BR (1) BR112020000413A2 (enExample)
CA (1) CA3069363A1 (enExample)
CO (1) CO2020000231A2 (enExample)
IL (1) IL271917A (enExample)
PE (1) PE20200613A1 (enExample)
PH (1) PH12020500087A1 (enExample)
RU (1) RU2020100072A (enExample)
SG (1) SG11202000197PA (enExample)
TW (1) TW201920674A (enExample)
WO (1) WO2019012371A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102020201219A1 (de) 2020-01-31 2021-08-05 United Initiators Gmbh Transport- und Lagerbehälter für Peroxide
CN112552380B (zh) * 2020-12-10 2021-12-24 武汉博沃生物科技有限公司 一种SARS-CoV-2病毒的免疫原及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
CA1341423C (en) 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5817491A (en) 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US6962790B1 (en) 1998-09-23 2005-11-08 University Of Massachusetts Medical Center Predictive assay for immune response
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
TWI228718B (en) 2001-11-05 2005-03-01 Tdk Corp Manufacturing method and device of mold plate for information medium
DE10162480A1 (de) * 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
DE602005017743D1 (de) 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
CN101522706B (zh) * 2006-10-12 2013-09-04 P.安杰莱蒂分子生物学研究所 端粒酶逆转录酶融合蛋白、编码它的核苷酸以及其用途
SG10201805844QA (en) 2008-07-08 2018-08-30 Incyte Holdings Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
KR101763093B1 (ko) 2009-02-02 2017-07-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도
US9128725B2 (en) 2012-05-04 2015-09-08 Apple Inc. Load-store dependency predictor content management
KR20240063172A (ko) * 2012-11-20 2024-05-09 사노피 항-ceacam5 항체 및 이의 용도
JP2014161283A (ja) * 2013-02-26 2014-09-08 Shizuoka Prefecture Ceacam5遺伝子のスプライシングバリアント
AU2014310932B2 (en) * 2013-08-21 2019-06-06 CureVac SE Composition and vaccine for treating lung cancer
US20160296577A1 (en) 2013-10-28 2016-10-13 Piramal Enterprises Limited Herbal composition, process for its preparation and use thereof
WO2015063647A1 (en) 2013-11-01 2015-05-07 Pfizer Inc. Vectors for expression of prostate-associated antigens
MD20160118A2 (ro) 2014-05-15 2017-04-30 Iteos Therapeutics Derivaţi ai pirolidin-2,5-dionei, compoziţii farmaceutice şi metode de utilizare ca inhibitori ai IDO1
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗pd-1抗體類和使用彼等之方法
JP6647315B2 (ja) * 2015-01-09 2020-02-14 イーチュービクス コーポレイション 組み合わせ免疫療法のための方法および組成物

Similar Documents

Publication Publication Date Title
JP3995712B2 (ja) 生の組換え細菌ワクチンベクターを用いる癌の特異的免疫療法
JP2022160401A5 (enExample)
TWI676636B (zh) 包含pd-1抗原或pd-1配體抗原的類病毒粒子
JP2018509936A5 (enExample)
JP2016505635A5 (enExample)
JP2017513502A5 (enExample)
JP2019536426A5 (enExample)
CN113056477A (zh) 用于在疾病的预防和/或治疗中使用的疫苗
CN114592010A (zh) NK-CAR-MbIL-15细胞及其制备方法和应用
JP2017510297A5 (enExample)
JP6406647B2 (ja) 細胞性免疫誘導ワクチン
JP2019517790A5 (enExample)
JP4033497B2 (ja) ワクチン製剤
JP2018536002A5 (enExample)
CN111154806A (zh) 一种嵌合外源超级细胞因子的溶瘤病毒载体系统及其在药物中的应用
JP6293882B2 (ja) 遺伝的に安定な腫瘍溶解性rnaウイルス、その製造方法およびその使用
JP2014139185A5 (enExample)
JP2020526202A5 (enExample)
JP2019505210A5 (enExample)
RU2018126487A (ru) Противораковые вакцины
RU2020100072A (ru) Иммуногенные композиции, содержащие cea, muc1 и tert
CN106177947A (zh) 免疫监测点阻断药物和肿瘤疫苗联合的制药用途
CN109790224A (zh) Cacna1h衍生的肿瘤抗原多肽及其应用
RU2011120447A (ru) Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины
US20240325510A1 (en) Novel anti-cancer vaccine composition and a method of vaccination using the same